MyoKardia, Inc. (MYOK): Price and Financial Metrics


MyoKardia, Inc. (MYOK)

Today's Latest Price: $90.62 USD

2.24 (-2.41%)

Updated Jul 13 6:55pm

Add MYOK to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MYOK Stock Summary

  • MYOK's price/sales ratio is 283.62; that's higher than the P/S ratio of 98.98% of US stocks.
  • Over the past twelve months, MYOK has reported earnings growth of 292.69%, putting it ahead of 95.71% of US stocks in our set.
  • As for revenue growth, note that MYOK's revenue has grown -53.7% over the past 12 months; that beats the revenue growth of merely 3.04% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to MyoKardia Inc are TRVN, MNTA, NBRV, NVCN, and INFI.
  • Visit MYOK's SEC page to see the company's official filings. To visit the company's web site, go to www.myokardia.com.
MYOK Daily Price Range
MYOK 52-Week Price Range

MYOK Stock Price Chart Technical Analysis Charts


MYOK Price/Volume Stats

Current price $90.62 52-week high $126.30
Prev. close $92.86 52-week low $42.65
Day low $90.20 Volume 329,500
Day high $95.79 Avg. volume 584,205
50-day MA $96.32 Dividend yield N/A
200-day MA $70.06 Market Cap 4.23B

MyoKardia, Inc. (MYOK) Company Bio


MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases


MYOK Latest News Stream


Event/TimeNews Detail
Loading, please wait...

MYOK Latest Social Stream


Loading social stream, please wait...

View Full MYOK Social Stream

Latest MYOK News From Around the Web

Below are the latest news stories about MyoKardia Inc that investors may wish to consider to help them evaluate MYOK as an investment opportunity.

Did Hedge Funds Make The Right Call On MyoKardia, Inc. (MYOK) ?

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each stock might be going. […]

Yahoo | July 13, 2020

MyoKardia Announces Appointment of Denelle J. Waynick as General Counsel and Corporate Secretary

MyoKardia, Inc. (MYOK) today announced the appointment of Denelle Waynick as General Counsel and Corporate Secretary. Ms. Waynick joins MyoKardia from UCB, Inc., bringing more than 25 years of domestic and international legal and business expertise in the healthcare and life-science industry. Cynthia Ladd, who has been leading MyoKardia’s legal function as General Counsel since January 2018, will be retiring this year.

Yahoo | July 6, 2020

MyoKardia (MYOK) Investor Presentation - Slideshow

The following slide deck was published by MyoKardia, Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | June 23, 2020

MyoKardia's danicamtiv shows positive action in mid-stage study

MyoKardia ([[MYOK]] -0.8%) announces positive results from a Phase 2a clinical trial evaluating danicamtiv in stable heart failure patients with reduced ejection fraction. The data were presented virtually at the European Society of Cardiology's Heart Failure Association Discoveries event.Treatment for seven days showed that danicamtiv was generally well-tolerated and was...

Seeking Alpha | June 22, 2020

MyoKardia Announces Positive Data from Phase 2a Clinical Trial of Danicamtiv Presented at ESC’s HFA Discoveries with Simultaneous Publication in European Journal of Heart Failure

MyoKardia, Inc. (MYOK) today announced the presentation and publication of positive data from the company’s Phase 2a clinical trial of danicamtiv (formerly MYK-491) along with nonclinical data elucidating danicamtiv’s novel mechanism of action. Results from both the clinical and nonclinical studies of danicamtiv were featured at the European Society of Cardiology’s Heart Failure Association (HFA) Discoveries online event and published simultaneously in the European Journal of Heart Failure.

Yahoo | June 22, 2020

Read More 'MYOK' Stories Here

MYOK Price Returns

1-mo -3.76%
3-mo 70.15%
6-mo 20.54%
1-year 80.45%
3-year 554.30%
5-year N/A
YTD 24.33%
2019 49.17%
2018 16.06%
2017 225.10%
2016 -11.66%
2015 N/A

Continue Researching MYOK

Here are a few links from around the web to help you further your research on MyoKardia Inc's stock as an investment opportunity:

MyoKardia Inc (MYOK) Stock Price | Nasdaq
MyoKardia Inc (MYOK) Stock Quote, History and News - Yahoo Finance
MyoKardia Inc (MYOK) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.8394 seconds.